Treatment of Depression in Medical Illness

Biology of Depression: From Novel Insights to Therapeutic Strategies

Volumn , Issue , 2008, Pages 253-278

  Raison, Charles L ^a   Purselle, David C ^a   Capuron, Lucile ^a   Miller, Andrew H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Disease; Medical illness; Parkinson's; Sick; Treatment

Indexed keywords

EID: 38649091537     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619672.ch9     Document Type: Chapter

References (149)

1. Blazer, D. G., Kessler, R. C., McGonagle, K. A., Swartz, M. S., The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am. J. Psychiatry 1994, 151 (7), 979-986.
2. Evans, D. L., Staab, J. P., Petitto, J. M., Morrison, M. F., Szuba, M. P., Ward, H. E., Wingate, B., Luber, M. P., O'Reardon, J. P., Depression in the medical setting: biopsychological interactions and treatment considerations. J. Clin. Psychiatry 1999, 60 (Suppl. 4), 40-55; discussion 56.
3. Simon, G. E., Vonkorff, M., Barlow, W, Health care costs of primary care patients with recognized depression. Arch. Gen. Psychiatry 1995, 52 (10), 850-856.
4. Raison, C. L., Miller, A. H., Depression in cancer: new developments regarding diagnosis and treatment. Biol. Psychiatry 2003, 54 (3), 283-294.
5. Cohen-Cole, S. A., Brown, F. W., Mcdaniel, J. S., Diagnostic assessment of depression in the medically ill. In: Stoudemire, A., Fogel, B. (Eds.), Psychiatric Care of the Medical Patient. New York: Oxford University Press, 1993, 53-70.
6. Max, M. B., Lynch, S. A., Muir, J., Shoaf, S. E., Smoller, B., Dubner, R., Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N. Engl. J. Med. 1992, 326 (19), 1250-1256.
7. Semenchuk, M. R., Sherman, S., Davis, B., Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001, 57 (9), 1583-1588.
8. Sumpton, J. E., Moulin, D. E., Treatment of neuropathic pain with venlafaxine. Ann. Pharmacother. 2001, 35 (5), 557-559.
9. Kast, R. E., Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 2001, 9 (6), 469-470.
10. Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., Lavasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., Christensen, B. J., Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000, 356 (9247), 2059-2063.
11. Stearns, V, Isaacs, C., Rowland, J., Crawford, J., Ellis, M. J., Kramer, R., Lawrence, W., Hanfelt, J. J., Hayes, D. F. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann. Oncol. 2000, 11 (1), 17-22.
12. Breslau, N., Roth, T., Rosenthal, L., Andreski, P., Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol. Psychiatry 1996, 39 (6), 411-418.
13. Gureje, O., Simon, G. E., Von Korff, M., A cross-national study of the course of persistent pain in primary care. Pain 2001, 92 (1-2), 195-200.
14. Van't Spijker, A., Trijsburg, R. W., Duivenvoorden, H. J., Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. Psychosom. Med. 1997, 59 (3), 280-293.
15. Krishnan, K. R., Delong, M., Kraemer, H., Carney, R., Spiegel, D., Gordon, C., Mcdonald, W., Dew, M., Alexopoulos, G., Buckwalter, K., Cohen, P. D., Evans, D., Kaufmann, P. G., Olin, J., Otey, E., Wainscott, C., Comorbidity of depression with other medical diseases in the elderly. Biol. Psychiatry 2002, 52 (6), 559-588.
16. Patten, S. B., Fong-term medical conditions and major depression in a Canadian population study at waves 1 and 2. J. Affect Disord. 2001, 63 (1-3), 35-41.
17. Mcdaniel, J. S., Musselman, D. L., Porter, M. R., Reed, D. A., Nemeroff, C. B., Depression in patients with cancer. Diagnosis, biology, and treatment. Arch. Gen. Psychiatry 1995, 52 (2), 89-99.
18. Carney, R. M., Rich, M. W., Tevelde, A., Saini, J., Clark, K., Jaffe, A. S., Major depressive disorder in coronary artery disease. Am. J. Cardiol. 1987, 60 (16), 1273-1275.
19. Frasure-Smith, N., Lesperance, F., Talajic, M., Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993, 270 (15), 1819-1825.
20. Gonzalez, M. B., Snyderman, T. B., Colket, J. T., Arias, R. M., Jiang, J. W., O'Connor, C. M., Krishnan, K. R., Depression in patients with coronary artery disease. Depression 1996, 4 (2), 57-62.
21. Mayou, R. A., Gill, D., Thompson, D. R., Day, A., Hicks, N., Volmink, J., Neil, A., Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom. Med. 2000. 62 (2), 212-219.
22. Schleifer, S. J., Macari-Hinson, M. M., Coyle, D. A., Slater, W. R., Kahn, M., Gorlin, R., Zucker, H. D., The nature and course of depression following myocardial infarction. Archiv Intern. Med. 1989, 149 (8), 1785-1789.
23. Anderson, R. J., Freedland, K. E., Clouse, R. E., Lustman, P. J., The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001, 24 (6), 1069-1078.
24. Ciesla, J. A., Roberts, J. E., Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am. J. Psychiatry 2001, 158 (5), 725-730.
25. Hakim, E. A., Bakheit, A. M., Bryant, T. N., Roberts, M. W., Mcintosh-Michaelis, S. A., Spackman, A. J., Martin, J. P., Mclellan, D. L., The social impact of multiple sclerosis-a study of 305 patients and their relatives. Disability Rehab. 2000, 22 (6), 288-293.
26. Patten, S. B., Metz, L. M., Reimer, M. A., Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Multiple Sclerosis 2000, 6 (2), 115-120.
27. Mayeux, R., Williams, J. B., Stern, Y., Cote, L., Depression and Parkinson's disease. Adv. Neurol. 1984, 40, 241-250.
28. Schrag, A., Jahanshahi, M., Quinn, N. P., What contributes to depression in Parkinson's disease? Psychol. Med. 2001, 31 (1), 65-73.
29. Starkstein, S. E., Preziosi, T. J., Bolduc, P. L., Robinson, R. G., Depression in Parkinson's disease. J. Nerv. Mental Dis. 1990, 178 (1), 27-31.
30. Whyte, E. M., Mulsant, B. H., Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol. Psychiatry 2002, 52 (3), 253-264.
31. Fras, I., Litin, E. M., Pearson, J. S., Comparison of psychiatric symptoms in carcinoma of the pancreas with those in some other intra-abdominal neoplasms. Am. J. Psychiatry 1967, 123 (12), 1553-1562.
32. Koenig, R., Levin, S. M., Brennan, M. J., The emotional status of cancer patients as measured by a psychological test. J. Chron. Dis. 1967, 20 (11), 923-930.
33. Colon, E. A., Callies, A. L., Popkin, M. K., Mcglave, P. B., Depressed mood and other variables related to bone marrow transplantation survival in acute leukemia. Psychosomatics 1991, 32 (4), 420-425.
34. Chochinov, H. M., Depression in cancer patients. Lancet Oncol. 2001, 2 (8), 499-505.
35. Raison, C. L., Miller, A. H., Depression in cancer: new developments regarding diagnosis and treatment. Biol. Psychiatry 2003, 54 (3), 283-294.
36. Schwab, J., Bialow, M., Clemmons, R., Martin, P., Holzer, C., The Beck Depression Inventory with medical inpatients. Acta Psychiatr. Scand. 1967, 43 (3), 255-266.
37. Knights, E. B., Folstein, M. F., Unsuspected emotional and cognitive disturbance in medical patients. Ann. Intern. Med. 1977, 87 (6), 723-724.
38. Moffic, H. S., Paykel, E. S., Depression in medical in-patients. Br. J. Psychiatry 1975, 126, 346-353.
39. Vonammon Cavanaugh, S., The prevalence of emotional and cognitive dysfunction in a general medical population: using the MMSE, GHQ, and BDI. Gen. Hosp. Psychiatry 1983, 5 (1), 15-24.
40. Katon, W., Sullivan, M. D., Depression and chronic medical illness. J. Clin. Psychiatry, 1990, 51 (Suppl.), 3-11; discussion 12-14.
41. Tranmer, J. E., Heyland, D., Dudgeon, D., Groll, D., Squires-Graham, M., Coulson, K., Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J. Pain Symptom Manag. 2003, 25 (5), 420-429.
42. Schaefer, M., Engelbrecht, M. A., Gut, O., Fiebich, B. L., Bauer, J., Schmidt, F., Grunze, H., Lieb, K., Interferon alpha (IFNa) and psychiatric syndromes: a review. Prog. Neuro-Psychopharmacol Biol. Psychiatry 2002, 26, 731-746.
43. Akechi, T., Nakano, T., Okamura, H., Ueda, S., Akizuki, N., Nakanishi, T., Yoshikawa, E., Matsuki, H., Hiraba-yashi, E., Uchitomi, Y., Psychiatric disorders in cancer patients: descriptive analysis of 1721 psychiatric referrals at two Japanese cancer center hospitals. Japanese J. Clin. Oncol. 2001, 31 (5), 188-194.
44. Chochinov, H. M., Wilson, K. G., Enns, M., Lander, S., Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments. Am. J. Psychiatry 1994, 151 (4), 537-540.
45. Burgess, C. C., Ramirez, A. J., Richards, M. A., Potts, H. W., Does the method of detection of breast cancer affect subsequent psychiatric morbidity? Eur. J. Cancer 2002, 38 (12), 1622-1625.
46. Wellisch, D. K., Kaleita, T. A., Freeman, D., Cloughesy, T., Goldman, J., Predicting major depression in brain tumor patients. Psycho-Oncology 2002, 11 (3), 230-238.
47. Akechi, T., Okamura, H., Nishiwaki, Y., Uchitomi, Y, Psychiatric disorders and associated and predictive factors in patients with unresectable nonsmall cell lung carcinoma: a longitudinal study. Cancer 2001, 92 (10), 2609-2622.
48. Raison, C. L., Demetrashvili, M., Capuron, L., Miller, A. H., Neuropsychiatric side effects of interferon-alpha: recognition and management. CNS Drugs 2004 (in press).
49. Harter, M., Reuter, K., Aschen-brenner, A., Schretzmann, B., Marschner, N., Hasenburg, A., Weis, J., Psychiatric disorders and associated factors in cancer: results of an interview study with patients in inpatient, rehabilitation and outpatient treatment. Eur. J. Cancer 2001, 37 (11), 1385-1393.
50. Maier, S. F., Watkins, L. R., Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol. Rev. 1998, 105 (1), 83-107.
51. Kent, S., Bluthe, R. M., Kelley, K. W., Dantzer, R., Sickness behavior as a new target for drug development. TIPS 1992, 13 (1), 24-28.
52. Dantzer, R., Cytokine-induced sickness behavior: mechanisms and implications. Ann. NY Acad. Sci. 2001, 933, 222-234.
53. Dunn, A. J., Wang, J., Ando, T., Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv. Exp. Med. Biol. 1999, 461, 117-127.
54. Yirmiya, R., Weidenfeld, J., Pollak, Y, Morag, M., Morag, A., Avitsur, R., Barak, O., Reichenberg, A., Cohen, E., Shavit, Y., Ovadia, H., Cytokines, "depression due to a general medical condition", and antidepressant drugs. Adv. Exp. Med. Biol. 1999, 461, 283-316.
55. Maier, S. F., Watkins, L. R., Intra-cerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res. 1995, 695 (2), 279-282.
56. Pugh, C. R., Nguyen, K. T., Gonyea, J. L., Fleshner, M., Wakins, L. R., Maier, S. F., Rudy, J. W., Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. Behav. Brain Res. 1999, 106 (1-2), 109-118.
57. Mathias, S. D., Colwell, H. H., Miller, D. P., Moreland, L. W., Buatti, M., Wanke, L., Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin. Ther. 2000, 22 (1), 128-139.
58. Musselman, D. L., Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry 2001, 158 (8), 1252-1257.
59. Allen-Mersh, T. G., Glover, C., Fordy, C., Henderson, D. C., Davies, M., Relation between depression and circulating immune products in patients with advanced colorectal cancer. J. Roy. Soc. Med. 1998, 91 (8), 408-413.
60. Capuron, L., Ravaud, A., Gualde, N., Bosmans, E., Dantzer, R., Maes, M., Neveu, P. J., Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001, 26 (8), 797-808.
61. Kahl, K. G., Kruse, N., Faller, H., Weiss, H., Rieckmann, P., Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002, 27 (6), 671-681.
62. Kozora, E., Laudenslager, M., Lemieux, A., West, S. G., Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. J. Int. Neuropsychol. Soc. 2001, 7 (6), 745-754.
63. Bower, J. E., Ganz, P. A., Aziz, N., Fahey, J. L., Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 2002, 64 (4), 604-611.
64. Greenberg, D. B., Gray, J. L., Mannix, C. M., Eisenthal, S., Carey, M., Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J. Pain Symptom Manag. 1993, 8 (4), 196-200.
65. Maes, M., Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. 1999, 461, 25-46.
66. Sommer, N., Loschmann, P. A., Northoff, G. H., Weller, M., Steinbrecher, A., Steinbach, J. P., Lichtenfels, R., Meyermann, R., Riethmuller, A., Fontana, A., The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med. 1995, 1 (3), 244-248.
67. Griswold, D. E., Webb, E. F., Badger, A. M., Gorycki, P. D., Levandoski, P. A., Barnette, M. A., Grous, M., Christensen, S., Torphy, T. J. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J. Pharmacol. Exp. Ther. 1998, 287 (2), 705-711.
68. Yaron, I., Shirazi, I., Judovich, R., Levartovsky, D., Caspi, D., Yaron, M., Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum. 1999, 42 (12), 2561-2568.
69. Song, C., Leonard, B. E., An acute phase protein response in the olfactory bulb-ectomized rat: effect of sertraline treatment. Med. Sci. Res. 1994, 22, 313-314.
70. Kubera, M., Symbirtsev, A., Basta-Kaim, A., Borycz, J., Roman, A., Papp, M., Claesson, M., Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by spleno-cytes obtained from rats subjected to a chronic mild stress model of depression. Pol. J. Pharmacol. 1996, 48 (5), 503-506.
71. Zhu, J., Bengtsson, B. O., Mix, E., Thorell, L. H., Olsson, T., Link, H., Effect of monoamine reuptake inhibiting antidepressants on major histocompatibility complex expression on macrophages in normal rats and rats with experimental allergic neuritis (EAN). Immuno-pharmacology 1994, 27 (3), 225-244.
72. Bianchi, M., Rossoni, G., Sacerdote, P., Panerai, A. E., Berti, F., Effects of chlomipramine and fluoxetine on subcutaneous carrageenin-induced inflammation in the rat. Inflammation Res. 1995, 44 (11), 466-469.
73. Michelson, D., Misiewicz-Poltorak, B., Raybourne, R. B., Gold, P. W., Sternberg, E. M., Imipramine reduces the local inflammatory response to carrageenin. Agents Actions 1994, 42 (1-2), 25-28.
74. Shen, Y., Connor, T. J., Nolan, Y., Kelly, J. P., Leonard, B. E., Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci. 1999, 65 (17), 1773-1786.
75. Yirmiya, R., Pollak, Y., Barak, O., Avitsur, R., Ovadia, H., Bette, M., Weihe, E., Weidenfeld, J., Effects of antidepressant drugs on the behavioral and physiological responses to lipopoly-saccharide (LPS) in rodents. Neuropsychopharmacology 2001, 24 (5), 531-544.
76. Dawson, L. A., Nguyen, H. Q., Geiger, A., Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism. Neuropharmacology 1999, 38 (8), 1153-1163.
77. Yirmiya, R., Endotoxin produces a depressive-like episode in rats. Brain Res. 1996, 711 (1-2), 163-174.
78. Castanon, N., Bluthe, R. M., Dantzer, R., Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology (Berl.) 2001, 154 (1), 50-60.
79. Dunn, A. J., Swiergiel, A. H., The reductions in sweetened milk intake induced by interleukin-1 and endotoxin are not prevented by chronic antidepressant treatment. Neuroimmuno-modulation 2001, 9 (3), 163-169.
80. Merali, Z., Brennan, K., Brau, P., Anisman, H., Dissociating anorexia and anhedonia elicited by interleukin-1beta: antidepressant and gender effects on responding for "free chow" and "earned" sucrose intake. Psychopharmacology (Berl.) 2003, 165 (4), 413-418.
81. Capuron, L., Gumnick, J. F., Musselman, D. L., Lawson, D. H., Reemsnyder, A., Nemeroff, C. B., Miller, A. H., Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26 (5), 643-652.
82. Raison, C. L., Miller, A. H., When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 2003, 160 (9), 1554-1565.
83. Brambilla, F., Maggioni, M., Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr. Scand. 1998, 97 (4), 309-313.
84. Maes, M., Meltzer, H. Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., Desnyder, R., Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect Disord. 1995, 34 (4), 301-309.
85. Landmann, R., Schaub, B., Link, S., Wacker, H. R., Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy. Biol. Psychiatry 1997, 41 (6), 675-681.
86. Weizman, R., Laor, N., Podliszewski, E., Notti, I., Djaldetti, M., Bessler, H., Cytokine production in major depressed patients before and after clomipramine treatment. Biol. Psychiatry 1994, 35 (1), 42-47.
87. Sluzewska, A., Rybakowski, J., Laciak, M., Mackiewicz, A., Sobieska, M., Wiktorowicz, K., Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. NY Acad. Sci. 1995, 762, 474-476.
88. Seidel, A., Arolt, V., Hunstiger, M., Rink, L., Behnisch, A., Kirchner, H., Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr. Scand. 1996, 94 (3), 198-204.
89. Tuglu, C., Kara, S. H., Caliyurt, O., Vardar, E., Abay, E., Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl.) 2003, 170, 429-433.
90. Hestad, K. A., Tonseth, S., Stoen, C. D., Ueland, T., Aukrust, P., Raised plasma levels of tumor necrosis factor alpha in patients with depression. J. ECT 2003, 19 (4), 183-188.
91. Roitt, I., Bostoff, J., Male, D., Immunology 5th ed. New York: Mosby, 1998.
92. Capuron, L., Raison, C. L., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Miller, A. H., Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am. J. Psychiatry 2003, 160 (7), 1342-1345.
93. Taylor, J. L., Grossberg, S. E., The effects of interferon-alpha on the production and action of other cytokines. Semin. Oncol. 1998, 25 (1 Suppl. 1), 23-29.
94. Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., Miller, A. H., Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 2001, 344 (13), 961-966.
95. Schaefer, M., Schwaiger, M., Berg, T., Citalopram for the prevention of inter-feron-alpha associated depression in psychiatric risk patients. Hepatology 2003, 38 (4, Suppl. 1), 320A.
96. Mohr, D. C., Goodkin, D. E., Likosky, W., Gatto, N., Baumann, K. A., Rudick, R. A., Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch. Neurol. 1997, 54 (5), 531-533.
97. Schramm, T. M., Lawford, B. R., Macdonald, G. A., Cooksley, W. G., Sertraline treatment of interferon-alfa-induced depressive disorder. Med. J. Aust. 2000, 173 (7), 359-361.
98. Gleason, O. C., Yates, W. R., Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999, 40 (6), 510-512.
99. Levenson, J. L., Fallon, H. J., Fluoxetine treatment of depression caused by interferon-alpha. Am. J. Gastroenterol. 1993, 88 (5), 760-761.
100. Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M. A., Hill, J., Gulati, M., Thornton, A. J., Schultz, R. L., Valentine, A. D., Meyers, C. A., Howell, C. D. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol. Psychiatry 2002, 7 (9), 942-947.
101. Kraus, M. R., Schafer, A., Faller, H., Csef, H., Scheurlen, M., Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Alim. Pharmacol. Ther. 2002, 16 (6), 1091-1099.
102. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-4th ed. 1994, Washington, DC: American Psychiatric Association.
103. Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., Engstrom, M. C., Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory. Cancer 2000, 89 (7), 1634-1646.
104. Morrow, G. R., Hickok, J. T., Roscoe, J. A., Raubertas, R. F., Andrews, P. L. R., Flynn, P. J., Hynes, H. E., Banerjee, T. K., Kirshner, J. J., King, D. K., Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J. Clin. Oncol. 2003, 21 (24), 4635-4641.
105. Krueger, J. M., Obal, F. J., Fang, J., Kubota, T., Taishi, P., The role of cytokines in physiological sleep regulation. Ann. NY Acad. Sci. 2001, 933, 211-221.
106. Rachal Pugh, C., Fleshner, M., Watkins, L. R., Maier, S. F., Rudy, J. W., The immune system and memory consolidation: a role for the cytokine IL-1beta. Neurosci. Biobehav. Rev. 2001, 25 (1), 29-41.
107. Owens, M. J., Nemeroff, C. B., Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 1991, 43 (4), 425-473.
108. Delgado, P. L., Miller, H. L., Salomon, R. M., Licinio, J., Krystal, J. H., Moreno, F. A., Heninger, G. R., Charney, D. S., Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol. Psychiatry 1999, 46 (2), 212-220.
109. Naranjo, C. A., Tremblay, L. K., Busto, U. E., The role of the brain reward system in depression. Prog. Neuro-Psychopharmacol Biol. Psychiatry 2001, 25 (4), 781-823.
110. Besedovsky, H., Del Rey, A., Sorkin, E., Dinarello, C. A., Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986, 233 (4764), 652-654.
111. Rivier, C., Influence of immune signals on the hypothalamic-pituitary axis of the rodent. Frontiers Neuroendocrinol. 1995, 16 (2), 151-182.
112. Raber, J., Koob, G. F., Bloom, F. E., Interferon-alpha and transforming growth factor-beta 1 regulate corticotropin-releasing factor release from the amygdala: comparison with the hypothalamic response. Neurochemist Int. 1997. 30 (4-5), 455-463.
113. Capuron, L., Neurauter, G., Mussel-man, D. L., Lawson, D., Nemeroff, C. B., Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol. Psychiatry 2003 (in press).
114. Shuto, H., Kataoka, Y., Horikawa, T., Fujihara, N., Oishi, R., Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res. 1997, 747 (2), 348-351.
115. Capuron, L., Miller, A. H., Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 2004 (in press).
116. Capuron, L., Ravaud, A., Neveu, P. J., Miller, A. H., Maes, M., Dantzer, R., Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 2002, 7 (5), 468-473.
117. Mellor, A. L., Munn, D. H., Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol. Today 1999, 20 (10), 469-473.
118. Moreno, F. A., Gelenberg, A. J., Heninger, G. R., Potter, R. L., McKnight, K. M., Allen, J., Phillips, A. P., Delgado, P. L., Tryptophan depletion and depressive vulnerability. Biol. Psychiatry 1999, 46 (4), 498-505.
119. Moreno, F. A., Heninger, G. R., McGahuey, C. A., Delgado, P. L., Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol. Psychiatry 2000, 48 (4), 327-329.
120. Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., Maes, M., Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J. Clin. Psycho-pharmacol. 2002, 22 (1), 86-90.
121. Widner, B., Ledochowski, M., Fuchs, D., Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences. Curr. Drug Metab. 2000, 1 (2), 193-204.
122. Holsboer, F., The corticosteroid hypothesis of depression. Neuropsychopharmacology 2000, 23, 477-501.
123. Cummings, J. L., Depression and Parkinson's disease: a review. Am. J. Psychiatry 1992, 149 (4), 443-454.
124. Berger, J. R., Arendt, G., HIV dementia: the role of the basal ganglia and dopaminergic systems. J. Psychopharmacol. 2000, 14 (3), 214-221.
125. Martinot, M., Bragulat, V., Artiges, E., Dolle, F., Hinnen, F., Jouvent, R., Martinot, J., Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am. J. Psychiatry 2001, 158 (2), 314-316.
126. Sugawara, Y., Akechi, T., Shima, Y., Okuyama, T., Akizuki, N., Nakano, T., Uchitomi, Y., Efficacy of methyl-phenidate for fatigue in advanced cancer patients: a preliminary study. Palliative Med. 2002, 16 (3), 261-263.
127. Sarhill, N., Walsh, D., Nelson, K. A., Homsi, J., Legrand, S., Davis, M. P., Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am. J. Hospice Palliative Care 2001, 18 (3), 187-192.
128. Zifko, U. A., Rupp, M., Schwarz, S., Zipko, H. T., Maida, E. M., Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J. Neurol. 2002, 249 (8), 983-987.
129. Capuron, L., Ravaud, A., Dantzer, R., Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom. Med. 2001, 63 (3), 376-386.
130. Sunami, M., Nishikawa, T., Yorogi, A., Shimoda, M., Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha. Clin. Neuropharmacol. 2000, 23 (1), 59-61.
131. Haas, H. S., Schauenstein, K., Neuroimmunomodulation via limbic structures-the neuroanatomy of psychoimmunology. Prog. Neurobiol. 1997, 51 (2), 195-222.
132. Gao, H. M., Jiang, J., Wilson, B., Zhang, W., Hong, J. S., Liu, B., Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 2002, 81 (6), 1285-1297.
133. Capuron, L., Pagnoni, G., Lawson, D., Demetrashvili, M., Woolwine, B. J., Kilts, C. D., Bremner, J. D., Nemeroff, C. B., Miller, A. H., Altered fronto-pallidal activity during high-dose interferon-alpha treatment as determined by positron emission tomography. Soc. Neurosci. Abstr.act 2002, 498.5.
134. Juengling, F. D., Ebert, D., Gut, O., Engelbrecht, M. A., Rasenack, J., Nitzsche, E. U., Bauer, J., Lieb, K., Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl.) 2000, 152 (4), 383-389.
135. Morrow, G. R., Hickok, J. T., Roscoe, J. A., Raubertas, R. F., Andrews, P. L., Flynn, P. J., Hynes, H. E., Banerjee, T. K., Kirshner, J. J., King, D. K., Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the university of Rochester cancer center community clinical oncology program. J. Clin. Oncol. 2003, 21 (24), 4635-4641.
136. Capuron, L., Miller, A. H., Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 2004 (in press).
137. Grippo, A. J., Francis, J., Weiss, R. M., Felder, R. B., Johnson, A. K., Cytokine mediation of experimental heart failure-induced anhedonia. Am. J. Physiol. -Reg. Integ. Comp. Physiol. 2003, 284 (3), R666-R673.
138. Lichtenstein, G. R., Bala, M., Han, C., Dewoody, K., Schaible, T., Infliximab improves quality of life in patients with Crohn's disease. Inflammatory Bowel Dis. 2002, 8 (4), 237-243.
139. Luheshi, G., Miller, A. J., Brouwer, S., Dascombe, M. J., Rothwell, N. J., Hopkins, S. J., Interleukin-1 receptor antagonist inhibits endotoxin fever and systemic interleukin-6 induction in the rat. Am. J. Physiol. 1996, 270 (1 Pt 1), E91-E95.
140. Opp, M. R., Krueger, J. M., Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever. Am. J. Physiol. 1991, 260 (2 Pt 2), R453-R457.
141. Gomez-Reino, J. J., Carmona, L., Valverde, V. R., Mola, E. M., Montero, M. D., Group, B., Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003, 48 (8), 2122-2127.
142. Kwon, H. J., Cote, T. R., Cuffe, M. S., Kramer, J. M., Braun, M. M., Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. 2003, 138 (10), 807-811.
143. Kroesen, S., Widmer, A. F., Tyndall, A., Hasler, P., Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003, 42 (5), 617-621.
144. Miller, A. H., Vogt, G., Pearce, B. D., The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function. Neuropsychopharmacology 2002, 27 (6), 939-948.
145. Goodnick, P. J., Treatment of chronic fatigue syndrome with venlafaxine. Am.J. Psychiatry 1996, 153 (2), 294.
146. Goodnick, P. J., Bupropion in chronic fatigue syndrome. Am. J. Psychiatry 1990, 147 (8), 1091.
147. Tran, P. V., Bymaster, F. P., Mcnamara, R. K., Potter, W. Z., Dual monoamine modulation for improved treatment of major depressive disorder. J. Clin. Psychopharmacol. 2003, 23 (1), 78-86.
148. Entsuah, A. R., Huang, H., Thase, M. E., Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J. Clin. Psychiatry 2001, 62 (11), 869-877.
149. Sauer, W. H., Berlin, J. A., Kimmel, S. E., Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003, 108 (1), 32-36.